Background
==========

Gastric cancer (GC) is a disease with very high morbidity and mortality worldwide; it was responsible for over 1 000 000 new cases and 783 000 deaths in 2018, which makes it the fifth most frequently diagnosed cancer and the third leading cause of cancer death \[[@b1-medscimonit-25-8777]\]. Although there has been significant progress in personalizing treatment for GC, it is still a clinically challenging disease characterized by a lack of effective treatment options and scarcely reliable molecular tools to predict patient outcomes. Compared with other cancer types, the clinical management of GC has not yet achieved the expected benefits from the era of personalized medicine \[[@b2-medscimonit-25-8777]\]. Almost one third of patients experience recurrence and distant metastasis after undergoing GC surgery \[[@b3-medscimonit-25-8777]\]. Therefore, the detection of molecular markers for early diagnosis, prognosis, and therapeutic targets of GC has become very urgent.

Most of the human genome is transcribed into non-protein-coding RNA, while protein-coding genome is less than 2% \[[@b4-medscimonit-25-8777]\]. Circular RNA (circRNA), as one of noncoding RNAs, are derived from the precursor messenger RNA (mRNA) of RNA transcriptase II, consisting of continuous covalently closed loop without the 5′-cap structure and the 3′-poly A tail. Due to this structure, circRNAs are not easily degraded by exonuclease RNase R \[[@b5-medscimonit-25-8777]\]. In particular, circRNAs are reported to play crucial roles in cancer occurrence, metastasis, and therapy resistance owning to its abundant biological effect on tumor cells including proliferation, apoptosis, and invasion \[[@b6-medscimonit-25-8777]\]. CircRNAs function primarily as transcriptional and post-transcriptional regulators through various functional mechanisms, such as RNA binding protein (RBP) sponges and protein scaffolds \[[@b7-medscimonit-25-8777]\], translate proteins \[[@b8-medscimonit-25-8777]\], RNAP II elongation \[[@b9-medscimonit-25-8777]\], RNA-RNA interactions \[[@b10-medscimonit-25-8777]\], and RNA maturation \[[@b11-medscimonit-25-8777]\]. At present, circRNAs function mainly by adsorbing microRNAs (miRNAs) as miRNA response elements (MRE) based on competing endogenous RNA (ceRNA) hypothesis in GC \[[@b12-medscimonit-25-8777],[@b13-medscimonit-25-8777]\]. For instance, augmented expression of circNF1 obviously promotes cell proliferation by sponging miR-16 in GC \[[@b14-medscimonit-25-8777]\]. Another study reported that has_circ_0001461 (termed circFAT1) low expression inhibited GC cell line proliferation by regulating the miR-548g/RUNX1 axis in the cytoplasm and targeting YBX1 in the nucleus, meanwhile, it was correlated with overall survival (OS) of GC patients \[[@b15-medscimonit-25-8777]\]. In addition, circRNA circPDSS1 has been shown to promote GC progression by sponging miR-186-5p to modulate NEK2 \[[@b16-medscimonit-25-8777]\].

Although several circRNAs have been identified as participating in the pathogenesis of GC, it is still necessary to conduct a circRNA-miRNA-mRNA regulatory network in GC, to help to advance our understanding of the molecular mechanism of GC. In the present study, we constructed a regulatory network consisting of 3 circRNAs, 22 miRNAs, and 128 mRNAs through multiple sets of the Gene Expression Omnibus (GEO) database and some online prediction websites, and analyzed the miRNAs and mRNAs in the network using The Cancer Genome Atlas (TCGA) database, the Gene Ontology (GO) analysis, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and the protein-protein interaction (PPI) network to indirectly understand the potential mechanism of circRNAs in the occurrence and development of GC

Material and Methods
====================

Data collection
---------------

The microarray data used in the current study were acquired from the GEO database (*<http://www.ncbi.nlm.nih.gov/gds/>*). The circRNAs expression data were obtained from GSE78092 (3 pairs of primary GC tissue and normal gastric mucosa) and GSE89143 (3 pairs of GC tissue and matched paracancerous tissue). The miRNA and mRNA expression data were respectively derived from GSE93415 (20 pairs of gastric tumor and adjacent healthy gastric mucosa) and GSE54129 (111 tumor samples and 21 normal gastric mucosa). GC level 3 miRNA-sequencing data and clinical information were downloaded from TCGA database (*<https://cancergenome.nih.gov/>*) on January 07, 2019. A total of 491 samples were included in this study, containing 446 GC samples and 45 matched normal samples. The detailed clinical information included sex, age at diagnosis, grade, T stage, N stage, M stage, and clinical stage, which is shown in Supplementary Table 1.

Differential expression analysis of circRNAs, miRNAs, and mRNAs
---------------------------------------------------------------

The downloaded platform file(s) and series of matrix file(s) were converted through using the R language software and annotation package. The ID of the corresponding probe name was converted into an international standard name (circRNA symbol). The analysis of differentially expressed RNAs was performed using the limma package based on the Bioconductor package. The criteria for selection of differentially expressed circRNAs (DEcircRNAs) were *P*-value \<0.05 and \|log2FC\| \>1. Differentially expressed miRNAs (DEmiRNAs) were identified by using GEO2R in dataset GSE93415, as the \|log2FC\| of most miRNAs is less than 1, we set the criterion that FDR values \<0.05 and \|log2FC\| \>0.5 were considered significantly. Differentially expressed mRNAs (DEmRNAs) were also identified by using GEO2R in dataset GSE54129, with the criterion that FDR values \<0.05 and \|log2FC\| \>1 were considered significantly. In addition, miRNA-sequencing data derived from TCGA were processed with edgeR \[[@b17-medscimonit-25-8777]\], a Bioconductor package based on the R language, to screen differentially expressed miRNAs (TDEmiRNAs) between GC tissue and adjacent normal tissue. Differentially expressed miRNAs with FDR values \<0.05 and \|log2FC\| \>1 were considered significantly.

Construction of the circRNA-miRNA-mRNA regulatory network
---------------------------------------------------------

According to the results of the differential expression analysis, we first get the intersection of DEcircRNAs between GSE78092 and GSE89143, called IDEcircRNAs. Targeting miRNAs of IDEcircRNAs were predicted via Cancer-Specific CircRNA Database (CSCD) *<http://gb.whu.edu.cn/CSCD/>* (we called it CPmiRNAs), then we took the intersection of it and DEmiRNAs, which we called ICPDEmiRNAs. Furthermore, we used Perl language to predict respectively their target genes according to downloaded miRNA databases on the 3 target gene prediction website including miRTarBase (*<http://mirtarbase.mbc.nctu.edu.tw/>*), targetScan (*<http://www.targetscan.org>*) and miRDB (*<http://www.mirdb.org/>*). Not all target genes were included, the miRNA target genes that could be found in all 3 databases were used as the final target genes, which were named TmRNA. We took the intersection of it and the DEmRNAs in the same way, and got the final functional genes, which were denominated FmRNAs, therefore, through IDEcircRNAs, ICPDEmiRNAs, and FmRNAs, we constructed the circRNA-miRNA-mRNA regulatory network using Cytoscape.

Functional enrichment analysis
------------------------------

We firstly converted the gene symbol of FmRNAs in the network into entrezIDs, meanwhile, installing R language packages including "colorspace", "stringi", "DOSE", "clusterProfiler", and "pathview". Furthermore, we obtained the outcomes of the GO analysis and the KEGG pathway through R studio and R scripting language, however, not all results were included. We set a criterion that the *P* value of the GO analysis was less than 0.05, besides the *P* value and q value of the KEGG analysis were both less than 0.05, and the network diagram of the KEGG pathway containing mRNA was constructed by Cytoscape.

The analysis of miRNAs and mRNA in the network
----------------------------------------------

We compared ICPDEmiRNAs and TDEmiRNAs by Venn diagram to find the sharing expressed miRNAs, whose expression in tumor tissues and normal tissues was plotted by GraphPad Prism 7, then we analyzed the clinical relevance via SPSS21.0. The hub genes of FmRNAs were screened by PPI and cytoHubba plugin. The medium confidence in the network was 0.400. In addition, their expression, survival prognosis and correlation with clinical stage were identified in GEPIA.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS 21.0 (Chicago, IL, USA). Significant differential expression levels of circRNAs were analyzed by R language limma packages and FDR filtering was used for comparative analysis. The *P*-value \<0.05 and absolute fold change ≥2.0 were considered statistically significant. The correlation between miRNA expression and clinical characteristics was tested by chi-square test.

Results
=======

Identification of DEcircRNA, DEmiRNAs, DEmRNAs
----------------------------------------------

The integrated analysis of GSE78092 and GSE89143 dataset respectively identified 112 and 54 differentially expressed circRNAs (DEcircRNAs) by R language limma packages, the former included 23 upregulated and 89 downregulated circRNAs, the latter had 8 and 54 ([Figure 1](#f1-medscimonit-25-8777){ref-type="fig"}). Then, we took the intersection of DEcircRNAs of the 2 datasets, the outcome showed that they didn't have common upregulated circRNAs, while having 3 sharing downregulated circRNAs (IDEcircRNAs) ([Figure 2A](#f2-medscimonit-25-8777){ref-type="fig"}), which were known as hsa_circ_004173, hsa_circ_0009076, hsa_circ_0028190 ([Figure 2B--2D](#f2-medscimonit-25-8777){ref-type="fig"}). Besides, we also used GEO2R online analysis on GSE93415 to obtain differentially expressed miRNAs. A total of 344 differentially expressed miRNAs were obtained, 149 of which were downregulated and 195 of which were upregulated (Supplementary Table 2). Similarly, we also did the same analysis on GSE54129, and found 3916 differentially expressed mRNAs, including 1896 upregulated mRNAs and 2020 downregulated mRNAs (Supplementary Table 3).

Searching for the relationship among circRNA, miRNA, and mRNA
-------------------------------------------------------------

The results of predicted targeting miRNAs on 3 circRNAs shown that hsa_circ_0009076 had 48 targeting miRNAs, hsa_circ_0028190 had 69, and hsa_circ_0041732 had 108. A total of 202 miRNAs were obtained after the removal of the repeatedly targeted miRNAs (Supplementary Table 4). We got 22 common miRNAs (ICPDEmiRNAs) ([Supplementary Figure 1A](#s1-medscimonit-25-8777){ref-type="supplementary-material"}) by taking the intersection of 202 targeting miRNAs and the precious 344 DEmiRNAs. In terms of target gene prediction, we obtained 431 target genes (TmRNAs) of 22 miRNAs (Supplementary Table 5). Finally, we obtained 128 common mRNAs (FmRNAs) ([Supplementary Figure 1B](#s1-medscimonit-25-8777){ref-type="supplementary-material"}) by intersecting the TmRNAs with the previously obtained 3916 DEmRNAs.

Constructing of circRNA-miRNA-mRNA network
------------------------------------------

From the previous data analysis, we got IDEcircRNAs including 3 downregulated circRNAs, 22 ICRDEmiRNAs including 13 upregulated, 9 downregulated, 128 FmRNAs including 69 upregulated and 59 downregulated. Then, we use Cytoscape Version3.6.1 soft to describe their relationships in the network, 3 circRNAs had 24 targeted relationship with 22 miRNAs, 22 miRNAs have 139 targeted relationship with 128 DEmiRNA-mRNAs ([Figure 3](#f3-medscimonit-25-8777){ref-type="fig"}).

The correlation of clinical characteristics and miRNAs
------------------------------------------------------

In order to further explore clinical correlation of miRNAs in the network, we first got 242 TDEmiRNAs including 178 upregulated and 69 downregulated (Supplementary Table 6, [Supplementary Figure 2](#s2-medscimonit-25-8777){ref-type="supplementary-material"}) in the stomach TCGA database. Compared with the precious 22 ICPDE miRNAs, we got the 3 same expression mode miRNAs. The situation of 3 miRNAs was displayed in [Figure 4](#f4-medscimonit-25-8777){ref-type="fig"}, then we analyzed their correlation with the clinical characteristics. The results were shown in [Table 1](#t1-medscimonit-25-8777){ref-type="table"}: hsa-mir-182 was associated with T stage (*P*=0.006) and N stage (*P*=0.013), hsa-mir-96 was associated with age (*P*=0.025), T stage (*P*=0.003) and N stage (*P*=0.042), and hsa-mir-195 was associated with N stage (*P*=0.029).

GO and KEGG analysis of FmRNAs
------------------------------

128 FmRNAs were used to detect the potential functions of circRNA, including GO enrichment analysis and KEGG pathway analysis. In the GO analysis, including biological process, cellular component and molecular function, we obtained 49 results, which were shown in [Table 2](#t2-medscimonit-25-8777){ref-type="table"}. In KEGG pathway analysis, we got 24 results, which were shown in [Table 3](#t3-medscimonit-25-8777){ref-type="table"}. The dotplot showed the results of the top 20 GO analysis results with *P* value from small to large, as well as the results of KEGG pathway, most of which were related to the density of tumor ([Figure 5A, 5B](#f5-medscimonit-25-8777){ref-type="fig"}). In addition, we also constructed the network diagram of the relationship between KEGG pathway and each mRNA ([Figure 5C](#f5-medscimonit-25-8777){ref-type="fig"}). In the tumor-associated signaling pathway, KEGG analysis showed that the PI3K-Akt signaling pathway contained the most genes (PRKAA1/MYC/CDK6/KRAS/LAMC1/THBS1/COL1A1/PPP2R5E/FOXO3) ([Supplementary Figure 3A](#s3-medscimonit-25-8777){ref-type="supplementary-material"}), and the p53 signaling pathway including PERP/APAF1/CDK6/SESN2/THBS1/SERPINE1 had the smallest *P*-value ([Supplementary Figure 3B](#s3-medscimonit-25-8777){ref-type="supplementary-material"}), which showed the most significance. The 2 signaling pathways became the focus of our observation.

Screening of hub genes
----------------------

In order to further find the hub genes of 128 FmRNAs in the network, STRING database (*<http://string-db.org>*), Cytoscape and its plugin (cytoHubba) were applied, and the results showed that 86 genes were related to each other ([Figure 6A](#f6-medscimonit-25-8777){ref-type="fig"}). According to cytoHubba plugin's MCC ranking, the top 10 hub genes were MYC (v-myc avian myelocytomatosis viral oncogene homolog), CTGF (connective tissue growth factor), TGFBR2 (TGF-beta receptor type-2), TGFBR1 (TGF-beta receptor type-1), SERPINE1 (plasminogen activator inhibitor 1), KRAS (Kirsten rat sarcoma viral oncogene homolog), ZEB1 (zinc finger E-box-binding homeobox 1), THBS 1 (thrombospondin-1), CDK6 (cyclin-dependent kinase 6), TNS1 (tensin-1) ([Figure 6B](#f6-medscimonit-25-8777){ref-type="fig"}, [Table 4](#t4-medscimonit-25-8777){ref-type="table"}). The expression of all the 10 genes was verified on the GEPIA, and it was found that MYC, TGFBR1, SERPINE1, and CDK6 showed statistically significant differences in expression ([Figure 7](#f7-medscimonit-25-8777){ref-type="fig"}). In addition, we also found that highly expressed SERPINE1 had a poor OS and disease-free survival (DFS), and TGFBR1 expression increased along with the increase of clinical stages ([Figure 8](#f8-medscimonit-25-8777){ref-type="fig"}) \[[@b18-medscimonit-25-8777]\].

Discussion
==========

Although the levels of diagnosis and treatment of GC is constantly improving, GC is still a high-risk disease, and a large part of its potential occurrence and development mechanism is still unclear. Prior to this, many studies on the pathogenesis of GC have been presented, but mainly focusing on genes encoding proteins. Since non-coding protein RNAs have appeared in everyone's field of vision and have been found to have specific regulatory functions, researchers have been investigating more and more non-coding RNAs, especially circRNAs. In this study, we discovered a few new circRNAs that target the regulation of downstream genes through sponge-adsorbed miRNAs. We also performed functional analysis of these target genes to understand the potential functions of these circRNAs.

In our study, we obtained a network of 3 circRNAs, 22 miRNAs, and 128 mRNAs using the GEO datasets. In addition, we found that on the CSCD website that hsa_circ_0009076 was composed of the 29^th^ and 30^th^ exons of the reverse transcript of the gene NRDC (location: 1p32.3, exon count: 35), hsa_circ_0028190 was composed of the 6^th^--11^th^ exons of the reverse transcript of the gene ANAPC7 (location: 12q24.11, exon count: 13), and hsa_circ_0041732 was composed of the 8^th^ exons of the forward transcript of the gene FAM64A (location: 17p13.2, exon count: 16). The 3 circRNAs have not been reported previous in the literature. We named hsa_circ_0009076, hsa_circ_0028190, and hsa_circ_0041732 respectively as circNRDC, circANAPC7, and circFAM64A. In the future, more experiments will be needed to verify the expression of these circRNAs and their effects on the proliferation, apoptosis, invasion, and metastasis of GC cells.

In order to explore the indirect mechanism of circRNAs on GC, miRNAs and mRNAs of circRNAs downstream in the regulatory network were further analyzed. We validated the 22 differentially expressed miRNAs in TCGA database and found that the 3 miRNAs had the same expression (has-miR-96, has-miR-182, and has-miR-195). The correlation with clinical features by chi-square test demonstrated that hsa-mir-182 was associated with T stage and N stage, hsa-mir-96 was associated with age, T stage, and N stage, and hsa-mir-195 was associated with N stage, although only 3 of the 22 miRNAs have been confirmed, which may be due to different sample and statistical methods; more experiments are needed to verify our results. Hsa-miR-96-5p has been reported in many studies, for example, miR-96 was successfully shown to increase expression in GC compared to normal or adenoma samples and was further validated with real-time quantitative polymerase chain reaction (RT-qPCR) in 77 samples \[[@b19-medscimonit-25-8777]\]. Hsa-miR-96 was shown to be upregulated in tumor tissues and HepG2 cells, and to promote tumorigenesis and progression by inhibiting FOXO1 and activating of AKT/GSK-3β/β-catenin signaling pathway in hepatocellular carcinoma \[[@b20-medscimonit-25-8777]\]. In addition, hsa-miR-96 accelerates invasion and migration of bladder cancer through epithelial-mesenchymal transition in response to transforming growth factor-β1 \[[@b21-medscimonit-25-8777]\]. One circRNA can adsorb multiple miRNAs, meanwhile, one miRNA can also be adsorbed by multiple circRNAs. In addition, we found that mir-182-5p in our network could be adsorbed by hsa_circ_0041732. Sun et al. showed that high expression of circ-SFMBT2 was related to the advanced progression of GC. The functional mechanism experiment showed that circ-SFMBT2 could regulate CREB1 by sponging mir-182-5p to promote the progression of GC \[[@b22-medscimonit-25-8777]\]. Li et al. showed that miR-182-5p had a higher expressed level through comparison between GC tissue and normal tissue, and improved the viability, mitosis, migration, and invasion ability of human GC cells by downregulating RAB27A \[[@b23-medscimonit-25-8777]\]. Wang et al. reported that expression levels of miR-195-5p and bFGF showed negative correlation in human GC tissues and miRNA-195 suppressed human GC by binding basic fibroblast growth factor \[[@b24-medscimonit-25-8777]\]. Ye et al. demonstrated that miR-195 overexpression restrained invasion, migration, and proliferation of GC cells *in vitro* and enhanced the chemotherapy sensitivity of cisplatin in GC cells, furthermore, benefiting survival prognosis of GC patients \[[@b25-medscimonit-25-8777]\]. These studies confirmed that the expression of the 3 miRNAs in our network was indeed involved in the occurrence and progression of GC.

Among KEGG tumor-related signaling pathways, PI3K-Akt signaling pathway contains the largest number of genes (PRKAA1/MYC/CDK6/KRAS/LAMC1/THBS1/COL1A1/PPP2R5E/FOXO3), while p53 signaling pathway (PERP/APAF1/CDK6/SESN2/THBS1/SERPINE1) has the smallest *P* value. We focused on these 2 signaling pathways. The PI3K/Akt signaling pathway functions as a vital intermediary to facilitate various cellular and physiological processes, including the cell cycle, cellular growth, differentiation, survival, apoptosis, metabolism, angiogenesis, and migration \[[@b26-medscimonit-25-8777]\]. Accumulating evidence has displayed that crucial epigenetic modifiers are directly or indirectly regulated by PI3K/AKT signaling and involved in oncogenesis of PI3K cascade in cancers \[[@b27-medscimonit-25-8777]\]. The core of p53 signaling pathway is p53, which functions as safeguarding the integrity of the genome. Activation of p53 affects apoptosis, cell cycle arrest, angiogenesis, DNA repair, and metastasis by mainly regulating downstream targeting genes \[[@b28-medscimonit-25-8777]\]. Wei et al. showed that overexpression of lncRNA MEG3 could increase the expression of p53, then its conclusion demonstrated that lncRNA MEG3 restrain proliferation and metastasis of GC via p53 signaling pathway \[[@b29-medscimonit-25-8777]\]. In our regulatory network, both THBS1 and CDK6 are involved in the regulation of PI3K-Akt and p53 signaling pathways. THBS1 was the first member of extracellular matrix (ECM) proteins family, which acts as an angiogenesis inhibitor and regulates tumor cell adhesion, invasion, migration, proliferation, apoptosis, and tumor immunity \[[@b30-medscimonit-25-8777],[@b31-medscimonit-25-8777]\]. CDK6 function cell-cycle progression, transcription, tissue homeostasis and differentiation as one member of cyclin-dependent kinases \[[@b32-medscimonit-25-8777]\]. A recent study found that the inhibition of hsa_circ_0081143 reduced GC cells invasion ability, viability, and increased the sensitivity of GC cells to cisplatin (DDP) *in vitro* act as an endogenous sponge adsorption by directly binding to miR-646 and efficiently inversing the inhibition of CDK6 \[[@b33-medscimonit-25-8777]\].

The 4 of top 10 hub genes (THBS1, CDK6, SERPINE1, TGFBR1) in the PPI network were consistent with the expression of GEPIA. Their survival analysis and clinical stage correlated with the expression were further explored. It was found that highly expressed SERPINE1 had a poor prognosis, and the expression of TGFBR1 was positively correlated with clinical stage. SERPINE1 encodes a member of the serine proteinase inhibitor (serpin) superfamily, which is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA). Overexpression of uPA/uPAR and SERPINE1 promotes tumor cell invasion and migration, playing an important role in metastasis development, conferring poor prognosis. In addition, both uPA/uPAR and SERPINE1 are directly associated with the induction of the acquisition of stem cell properties, epithelial-to-mesenchymal transition and resistance to antitumor agents \[[@b34-medscimonit-25-8777]\]. The protein encoded by TGFBR1, as a serine/threonine protein kinase, forms a heteromeric complex with type II TGF-beta receptors when bound to TGF-beta, transducing the TGF-beta signal from the cell surface to the cytoplasm, which participated in the regulation of various cell physiology and pathological processes, including adhesion, motility, differentiation, division and apoptosis, and plays a vital role in tumor invasion and metastasis by mediating epithelial-to-mesenchymal transition (EMT) \[[@b35-medscimonit-25-8777]\]. So in our regulatory network, we found 4 important circRNA-miRNA-mRNA axis including hsa_circ_0041732/hsa-mir-182-5p/THBS1, hsa_circ_0028190/hsa-mir-4291/CDK6, hsa_circ_0009076/hsa-mir-143-3p/SERPINE1, and hsa_circ_0028190/hsa-mir-140-5p/TGFBR1 about the 3 circRNAs. In future studies, more experiments are expected to verify this possible ceRNA mechanism in GC.

Conclusions
===========

Although there are some studies on circRNA in GC, the number and methods of research are different. In this study, we constructed a circRNA-miRNA-mRNA regulatory network including 3 important circRNAs (hsa_circ_0009076, hsa_circ_0028190, and hsa_circ_0041732) through multiple GEO databases and TCGA database and performed functional enrichment analysis on these final target genes for understanding the potential functional mechanisms of circRNA. Of course, it is more important to combine basic experiments with clinical data to further explore the feasibility of these circRNAs, so as to provide new molecular marker of prediction, prognosis, and therapeutic targets for clinical patients.

Supplementary Data
==================

Supplementary Tables 1--6 available from the corresponding author on request.

###### 

(**A**) The intersection of targeting mRNAs and DEmRNAs. (**B**) The intersection of targeting miRNAs and DEmiRNAs. mRNA -- messenger RNA; DE -- differentially expressed; miRNA -- microRNA.

###### 

Heatmap of differentially expressed miRNAs in gastric cancer on TCGA. miRNA -- microRNA; TCGA -- The Caner Genome Atlas

###### 

(**A**) PI3K-Akt signaling pathway diagram; (**B**) p53 signaling pathway diagram. Red represents upregulated mRNAs, blue represents downregulated mRNAs. mRNA --messenger RNA; miRNA -- mircoRNA.
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![Differentially expressed circular RNAs (DEcircRNAs). (**A**) Heatmap of GSE78092. (**B**) Volcano plot of GSE78092. (**C**) Heatmap of GSE89143. (**D**) Volcano plot of GSE89143.](medscimonit-25-8777-g001){#f1-medscimonit-25-8777}

![The intersection of circular RNAs (circRNAs). (**A**) Three sharing downregulated circRNAs. (**B**) Structure diagram of hsa_circ_0041732. (**C**) Structure diagram of hsa_circ_0009076. (**D**) Structure diagram of hsa_circ_0028190. The red, blue, and green regions inside the circular RNA molecule respectively represent MRE (microRNA response element), RBP (RNA binding protein), ORF (open reading frame).](medscimonit-25-8777-g002){#f2-medscimonit-25-8777}

![The circRNA-miRNA-mRNA regulatory network. The hexagon, ellipse, rectangle respectively circRNAs, mRNAs, and miRNAs. Red represents upregulated RNAs, Blue represents downregulated RNAs. circRNA -- circular RNA; miRNA -- microRNA; mRNA -- messenger RNA.](medscimonit-25-8777-g003){#f3-medscimonit-25-8777}

![Expression of 3 microRNAs in gastric cancer and normal tissues: (**A**) hsa-miR-96; (**B**) hsa-miR-182; (**C**) hsa-miR-195.](medscimonit-25-8777-g004){#f4-medscimonit-25-8777}

![Functional analysis of 128 DEmi-mRNAs. (**A**) The dotplot of top 20 GO analysis. (**B**) The dotplot of KEGG pathway. (**C**) The network diagram between KEGG pathways and mRNA. The larger the circle, the more genes it contained; conversely, the smaller the circle, the fewer genes it contained. The color of the circle is correlated with the *P*-value. The smaller the *P*-value is, the closer it is to the red value. The larger the *P*-value is, the closer it is to the blue value. DE -- differentially expressed; mi -- micro; m -- messenger; GO -- Gene Ontology; KEGG -- Kyoto Encyclopedia of Genes and Genomes.](medscimonit-25-8777-g005){#f5-medscimonit-25-8777}

![(**A**) PPI network diagram of 86 DEmi-mRNAs. (**B**) The network diagram of top 10 hub genes. PPI -- protein-protein interaction; DE -- differentially expressed; miRNA -- microRNA; mRNA -- messenger RNA.](medscimonit-25-8777-g006){#f6-medscimonit-25-8777}

![Four hub genes expression in GEPIA; (**A**) MYC, (**B**) CDK6, (**C**) SERPINE, (**D**) TGFBR1.](medscimonit-25-8777-g007){#f7-medscimonit-25-8777}

![(**A**) Disease-free survival of SERPINE; (**B**) overall survival of SERPINE. (**C**) Relationship between clinical stage and TGFBR1 expression.](medscimonit-25-8777-g008){#f8-medscimonit-25-8777}

###### 

Clinical correlation of 3 miRNAS.

  Variables               Numbers   hsa-miR-182   χ2 test P value   hsa-miR-96   χ2 test P value   hsa-miR-195   χ2 test P value               
  ----------------------- --------- ------------- ----------------- ------------ ----------------- ------------- ----------------- ----- ----- -------
  **Gender**                                                                                                                                   
  Female                  138       66            72                0.495        68                70            0.799             74    64    0.134
  Male                    235       121           114                            119               116                             113   122   
  **Age at diagnosis**                                                                                                                         
  \>50                    341       176           165               0.062        177               164           0.025             20    12    0.134
  ≤50                     32        11            21                             10                22                              167   174   
  **Grade**                                                                                                                                    
  G1                      6         4             2                 0.414        2                 4             0.407             4     2     0.414
  G2+G3                   367       183           184                            185               182                             183   184   
  **T stage**                                                                                                                                  
  T1+2                    97        37            60                0.006        36                61            0.003             56    41    0.405
  T3+4                    276       150           126                            151               125                             131   145   
  **Metastasis**                                                                                                                               
  M0                      345       168           177               0.051        170               175           0.244             174   171   0.683
  M1                      28        199           9                              17                11                              13    15    
  **Lymph node status**                                                                                                                        
  N0                      120       49            71                0.013        51                69            0.042             70    50    0.029
  N1--2                   253       138           115                            136               117                             117   136   
  **Stage**                                                                                                                                    
  I+II                    169       81            88                0.438        79                90            0.234             89    80    0.374
  III+IV                  204       106           98                             108               96                              98    106   

###### 

The results of GO enrichment analysis.

  ID            Description                                                                                                                                                                                         Gene ratio
  ------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  GO: 0001968   Fibronectin binding                                                                                                                                                                                 4/122
  GO: 0005201   Extracellular matrix structural constituent                                                                                                                                                         7/122
  GO: 0019888   Protein phosphatase regulator activity                                                                                                                                                              5/122
  GO: 0046332   SMAD binding                                                                                                                                                                                        5/122
  GO: 0019838   Growth factor binding                                                                                                                                                                               6/122
  GO: 0050431   Transforming growth factor beta binding                                                                                                                                                             3/122
  GO: 0019208   Phosphatase regulator activity                                                                                                                                                                      5/122
  GO: 0001227   Transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding                                                                                 7/122
  GO: 0001221   Transcription cofactor binding                                                                                                                                                                      3/122
  GO: 0004864   Protein phosphatase inhibitor activity                                                                                                                                                              3/122
  GO: 0019212   Phosphatase inhibitor activity                                                                                                                                                                      3/122
  GO: 0072542   Protein phosphatase activator activity                                                                                                                                                              2/122
  GO: 0048185   Activin binding                                                                                                                                                                                     2/122
  GO: 0004857   Enzyme inhibitor activity                                                                                                                                                                           8/122
  GO: 0004674   Protein serine/threonine kinase activity                                                                                                                                                            9/122
  GO: 0005024   Transforming growth factor beta-activated receptor activity                                                                                                                                         2/122
  GO: 0030169   Low-density lipoprotein particle binding                                                                                                                                                            2/122
  GO: 0070888   E-box binding                                                                                                                                                                                       3/122
  GO: 0019211   Phosphatase activator activity                                                                                                                                                                      2/122
  GO: 0004675   Transmembrane receptor protein serine/threonine kinase activity                                                                                                                                     2/122
  GO: 0003779   Actin binding                                                                                                                                                                                       8/122
  GO: 0001223   Transcription coactivator binding                                                                                                                                                                   2/122
  GO: 0030742   GTP-dependent protein binding                                                                                                                                                                       2/122
  GO: 0019955   Cytokine binding                                                                                                                                                                                    4/122
  GO: 0005518   Collagen binding                                                                                                                                                                                    3/122
  GO: 0017022   Myosin binding                                                                                                                                                                                      3/122
  GO: 0019903   Protein phosphatase binding                                                                                                                                                                         4/122
  GO: 0005520   Insulin-like growth factor binding                                                                                                                                                                  2/122
  GO: 0071813   Lipoprotein particle binding                                                                                                                                                                        2/122
  GO: 0071814   Protein-lipid complex binding                                                                                                                                                                       2/122
  GO: 0030332   Cyclin binding                                                                                                                                                                                      2/122
  GO: 0035035   Histone acetyltransferase binding                                                                                                                                                                   2/122
  GO: 0051721   Protein phosphatase 2A binding                                                                                                                                                                      2/122
  GO: 0019199   Transmembrane receptor protein kinase activity                                                                                                                                                      3/122
  GO: 0003713   Transcription coactivator activity                                                                                                                                                                  6/122
  GO: 1901682   Sulfur compound transmembrane transporter activity                                                                                                                                                  2/122
  GO: 0030020   Extracellular matrix structural constituent conferring tensile strength                                                                                                                             2/122
  GO: 0043531   ADP binding                                                                                                                                                                                         2/122
  GO: 0001078   Transcriptional repressor activity, RNA polymerase II proximal promoter sequence-specific DNA binding                                                                                               4/122
  GO: 0019902   Phosphatase binding                                                                                                                                                                                 4/122
  GO: 0000982   Transcription factor activity, RNA polymerase II proximal promoter sequence-specific DNA binding                                                                                                    7/122
  GO: 0019887   l kinase regulator activity                                                                                                                                                                         4/122
  GO: 0001228   Transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding                                                                                 7/122
  GO: 0016706   Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors   2/122
  GO: 0051018   Protein kinase A binding                                                                                                                                                                            2/122
  GO: 0045309   Protein phosphorylated amino acid binding                                                                                                                                                           2/122
  GO: 0005160   Transforming growth factor beta receptor binding                                                                                                                                                    2/122
  GO: 0031625   Ubiquitin protein ligase binding                                                                                                                                                                    5/122
  GO: 0031490   Chromatin DNA binding                                                                                                                                                                               3/122

  ID            Bg ratio    p Value       p Adjust      q Value       Gene ID                                                         Count
  ------------- ----------- ------------- ------------- ------------- --------------------------------------------------------------- -------
  GO: 0001968   27/17632    3.39E-05      0.012118429   0.011010275   CTGF/FSTL3/THBS1/IGFBP5                                         4
  GO: 0005201   155/17632   0.00010192    0.018243653   0.016575386   FBN2/MUC17/LAMC1/THBS1/TGFBI/COL1A1/COL5A2                      7
  GO: 0019888   80/17632    0.000232027   0.020766389   0.018867433   PHACTR2/PPP2R5E/PPP1R9B/PPP1R10/CALM2                           5
  GO: 0046332   80/17632    0.000232027   0.020766389   0.018867433   PRDM16/MYOCD/TGFBR1/COL5A2/TGFBR2                               5
  GO: 0019838   137/17632   0.000381094   0.025089597   0.022795311   CTGF/THBS1/IGFBP5/TGFBR1/COL1A1/TGFBR2                          6
  GO: 0050431   22/17632    0.000452113   0.025089597   0.022795311   THBS1/TGFBR1/TGFBR2                                             3
  GO: 0019208   94/17632    0.000490579   0.025089597   0.022795311   PHACTR2/PPP2R5E/PPP1R9B/PPP1R10/CALM2                           5
  GO: 0001227   267/17632   0.002578004   0.098990696   0.089938622   FOXO1/MYC/ZEB1/HEYL/PRDM1/PRRX1/FOXO3                           7
  GO: 0001221   41/17632    0.002844169   0.098990696   0.089938622   CCNT2/FOXO1/FOXO3                                               3
  GO: 0004864   41/17632    0.002844169   0.098990696   0.089938622   PHACTR2/PPP1R9B/PPP1R10                                         3
  GO: 0019212   44/17632    0.003480829   0.098990696   0.089938622   PHACTR2/PPP1R9B/PPP1R10                                         3
  GO: 0072542   13/17632    0.003523642   0.098990696   0.089938622   PPP2R5E/CALM2                                                   2
  GO: 0048185   14/17632    0.004092371   0.098990696   0.089938622   FSTL3/TGFBR1                                                    2
  GO: 0004857   371/17632   0.004286672   0.098990696   0.089938622   PHACTR2/TXNIP/SOCS3/PRKAR1A/PPP1R9B/PPP1R10/SERPINH1/SERPINE1   8
  GO: 0004674   455/17632   0.004378555   0.098990696   0.089938622   TRPM7/CCNT2/MKNK2/PDIK1L/PRKAA1/CDK6/UHMK1/TGFBR1/TGFBR2        9
  GO: 0005024   15/17632    0.004700676   0.098990696   0.089938622   TGFBR1/TGFBR2                                                   2
  GO: 0030169   15/17632    0.004700676   0.098990696   0.089938622   LDLR/THBS1                                                      2
  GO: 0070888   50/17632    0.004998838   0.099421342   0.090329887   CLOCK/MYC/ZEB1                                                  3
  GO: 0019211   16/17632    0.005347991   0.100767416   0.091552872   PPP2R5E/CALM2                                                   2
  GO: 0004675   17/17632    0.006033758   0.108004271   0.098127961   TGFBR1/TGFBR2                                                   2
  GO: 0003779   421/17632   0.00895487    0.148900927   0.135284877   MYO6/WASF2/TRPM7/PHACTR2/TNS1/MAP1B/CXCR4/PPP1R9B               8
  GO: 0001223   21/17632    0.009150336   0.148900927   0.135284877   CCNT2/FOXO1                                                     2
  GO: 0030742   22/17632    0.010020159   0.155965948   0.141703845   RAPGEF6/RAB34                                                   2
  GO: 0019955   125/17632   0.011123838   0.160730102   0.146032348   THBS1/CXCR4/TGFBR1/TGFBR2                                       4
  GO: 0005518   67/17632    0.011224169   0.160730102   0.146032348   THBS1/TGFBI/SERPINH1                                            3
  GO: 0017022   68/17632    0.011683934   0.160878783   0.146167433   TRPM7/RAB27A/CXCR4                                              3
  GO: 0019903   133/17632   0.013712012   0.181811121   0.16518564    FOXO1/SIRPA/STRN4/PPP1R9B                                       4
  GO: 0005520   28/17632    0.015960482   0.185140606   0.168210665   CTGF/IGFBP5                                                     2
  GO: 0071813   28/17632    0.015960482   0.185140606   0.168210665   LDLR/THBS1                                                      2
  GO: 0071814   28/17632    0.015960482   0.185140606   0.168210665   LDLR/THBS1                                                      2
  GO: 0030332   29/17632    0.017066033   0.185140606   0.168210665   FBXW7/CDK6                                                      2
  GO: 0035035   29/17632    0.017066033   0.185140606   0.168210665   MYOCD/CITED2                                                    2
  GO: 0051721   29/17632    0.017066033   0.185140606   0.168210665   FOXO1/STRN4                                                     2
  GO: 0019199   81/17632    0.018648344   0.196356092   0.178400566   EPHA4/TGFBR1/TGFBR2                                             3
  GO: 0003713   321/17632   0.024230576   0.247844173   0.225180387   PRDM16/RARG/ZEB1/PRRX1/MYOCD/CITED2                             6
  GO: 1901682   36/17632    0.025665148   0.255225634   0.231886859   SLC35B3/SLC19A3                                                 2
  GO: 0030020   37/17632    0.027010862   0.261348336   0.237449679   COL1A1/COL5A2                                                   2
  GO: 0043531   39/17632    0.02978569    0.274678286   0.249560689   MYO6/APAF1                                                      2
  GO: 0001078   169/17632   0.029923053   0.274678286   0.249560689   FOXO1/HEYL/PRDM1/PRRX1                                          4
  GO: 0019902   178/17632   0.035210199   0.304397033   0.276561844   FOXO1/SIRPA/STRN4/PPP1R9B                                       4
  GO: 0000982   447/17632   0.03582466    0.304397033   0.276561844   KLF5/FOXO1/MYC/HEYL/PRDM1/PRRX1/MYOCD                           7
  GO: 0019887   180/17632   0.036454143   0.304397033   0.276561844   CCNT2/SOCS3/PRKAR1A/CALM2                                       4
  GO: 0001228   449/17632   0.036561655   0.304397033   0.276561844   KLF5/CLOCK/MYC/HEYL/VEZF1/MYOCD/FOXO3                           7
  GO: 0016706   47/17632    0.041933365   0.341185106   0.30998588    TET3/P4HA2                                                      2
  GO: 0051018   48/17632    0.043562833   0.346566539   0.314875215   WASF2/PRKAR1A                                                   2
  GO: 0045309   49/17632    0.045215614   0.351895431   0.319716813   FBXW7/SOCS3                                                     2
  GO: 0005160   51/17632    0.04858954    0.352879061   0.320610497   TGFBR1/TGFBR2                                                   2
  GO: 0031625   286/17632   0.048696742   0.352879061   0.320610497   FOXO1/FBXW7/TXNIP/CXCR4/PRKAR1A                                 5
  GO: 0031490   119/17632   0.049642361   0.352879061   0.320610497   CLOCK/PRDM1/FOXO3                                               3

###### 

The results of KEGG pathway analysis.

  ID         Description                                            Gene ratio   Bg ratio   p Value
  ---------- ------------------------------------------------------ ------------ ---------- -------------
  hsa04218   Cellular senescence                                    10/57        160/7466   2.80E-07
  hsa04115   p53 signaling pathway                                  6/57         72/7466    1.60E-05
  hsa04910   Insulin signaling pathway                              7/57         137/7466   7.39E-05
  hsa04933   AGE-RAGE signaling pathway in diabetic complications   6/57         99/7466    9.81E-05
  hsa05220   Chronic myeloid leukemia                               5/57         76/7466    0.000265202
  hsa04068   FoxO signaling pathway                                 6/57         132/7466   0.000472257
  hsa04211   Longevity regulating pathway                           6/57         89/7466    0.000552582
  hsa04371   Apelin signaling pathway                               6/57         137/7466   0.000575675
  hsa05165   Human papillomavirus infection                         9/57         330/7466   0.000794412
  hsa04390   Hippo signaling pathway                                6/57         154/7466   0.001064365
  hsa05160   Hepatitis C                                            6/57         155/7466   0.001100757
  hsa04213   Longevity regulating pathway - multiple species        6/57         62/7466    0.00122559
  hsa04151   PI3K-Akt signaling pathway                             9/57         354/7466   0.0013066
  hsa04137   Mitophagy -- animal                                    4/57         65/7466    0.001462455
  hsa04520   Adherens junction                                      4/57         72/7466    0.002136126
  hsa05212   Pancreatic cancer                                      4/57         75/7466    0.002481334
  hsa05202   Transcriptional misregulation in cancer                6/57         186/7466   0.002786785
  hsa05219   Bladder cancer                                         3/57         41/7466    0.003662102
  hsa04350   TGF-beta signaling pathway                             4/57         85/7466    0.003907022
  hsa05210   Colorectal cancer                                      4/57         86/7466    0.004074595
  hsa04015   Rap1 signaling pathway                                 6/57         206/7466   0.004611998
  hsa05161   Hepatitis B                                            5/57         144/7466   0.004659537
  hsa05222   Small cell lung cancer                                 4/57         93/7466    0.005385847
  hsa05163   Human cytomegalovirus infection                        6/57         225/7466   0.007051458

  ID         p\. Adjust    q Value       Gene ID                                                        Count
  ---------- ------------- ------------- -------------------------------------------------------------- -------
  hsa04218   4.68E-05      3.51E-05      TRPM7/FOXO1/MYC/CDK6/KRAS/TGFBR1/TGFBR2/SERPINE1/CALM2/FOXO3   10
  hsa04115   0.001338182   0.001003742   PERP/APAF1/CDK6/SESN2/THBS1/SERPINE1                           6
  hsa04910   0.004095217   0.003071736   FOXO1/MKNK2/PRKAA1/KRAS/SOCS3/PRKAR1A/CALM2                    7
  hsa04933   0.004095217   0.003071736   FOXO1/KRAS/TGFBR1/COL1A1/TGFBR2/SERPINE1                       6
  hsa05220   0.008857732   0.006643997   MYC/CDK6/KRAS/TGFBR1/TGFBR2                                    5
  hsa04068   0.012017218   0.00901386    FOXO1/PRKAA1/KRAS/TGFBR1/TGFBR2/FOXO3                          6
  hsa04211   0.012017218   0.00901386    FOXO1/PRKAA1/KRAS/SESN2/FOXO3                                  5
  hsa04371   0.012017218   0.00901386    PRKAA1/KRAS/CTGF/TGFBR1/SERPINE1/CALM2                         6
  hsa05165   0.014740748   0.011056723   FOXO1/PARD6B/CDK6/KRAS/HEYL/LAMC1/THBS1/COL1A1/PPP2R5E         9
  hsa04390   0.016711491   0.012534935   PARD6B/MYC/CTGF/TGFBR1/TGFBR2/SERPINE1                         6
  hsa05160   0.016711491   0.012534935   LDLR/APAF1/MYC/CDK6/KRAS/SOCS3                                 6
  hsa04213   0.016784782   0.012589909   FOXO1/PRKAA1/KRAS/FOXO3                                        4
  hsa04151   0.016784782   0.012589909   PRKAA1/MYC/CDK6/KRAS/LAMC1/THBS1/COL1A1/PPP2R5E/FOXO3          9
  hsa04137   0.017444997   0.013085122   OPTN/KRAS/CITED2/FOXO3                                         4
  hsa04520   0.023782202   0.017838526   WASF2/CTNND1/TGFBR1/TGFBR2                                     4
  hsa05212   0.025898925   0.019426234   CDK6/KRAS/TGFBR1/TGFBR2                                        4
  hsa05202   0.027376065   0.020534206   CCNT2/FOXO1/MYC/ZEB1/AFF1/TGFBR2                               6
  hsa05219   0.033976167   0.025484802   MYC/KRAS/THBS1                                                 3
  hsa04350   0.03402287    0.025519833   MYC/THBS1/TGFBR1/TGFBR2                                        4
  hsa05210   0.03402287    0.025519833   MYC/KRAS/TGFBR1/TGFBR2                                         4
  hsa04015   0.03537012    0.026530377   PARD6B/RAPGEF6/CTNND1/KRAS/THBS1/CALM2                         6
  hsa05161   0.03537012    0.026530377   APAF1/MYC/CDK6/KRAS/TGFBR1                                     5
  hsa05222   0.03910593    0.029332528   APAF1/MYC/CDK6/LAMC1                                           4
  hsa05163   0.049066392   0.03680366    B2M/MYC/CDK6/KRAS/CXCR4/CALM2                                  6

###### 

The rank of hub genes via various of situations.

  Node name   MCC   DMNC      MNC   Degree   EPC      Bottle neck   Ec centricity   Closeness   Radiality   Betweenness   Stress   Clustering coefficient
  ----------- ----- --------- ----- -------- -------- ------------- --------------- ----------- ----------- ------------- -------- ------------------------
  MYC         609   0.24794   25    30       36.302   49            0.22965         50.91667    5.72361     2930.436      6766     0.13563
  CTGF        401   0.37042   13    14       35.37    8             0.18372         40.61667    5.33497     676.2413      2134     0.31868
  TGFBR2      396   0.49882   10    10       34.088   3             0.18372         38.03333    5.25253     183.2476      1158     0.55556
  TGFBR1      396   0.49882   10    10       33.892   1             0.18372         38.03333    5.25253     183.2476      1158     0.55556
  SERPINE1    370   0.5012    9     11       34.56    8             0.18372         39.45       5.34675     868.6996      2280     0.38182
  KRAS        322   0.36053   15    17       36.072   16            0.18372         42.76667    5.39386     828.0731      2704     0.26471
  ZEB1        318   0.45368   12    12       35.42    8             0.18372         39.2        5.28787     194.055       870      0.4697
  THBS1       259   0.41901   10    11       33.93    6             0.18372         38.61667    5.26431     402.2999      1202     0.38182
  CDK6        250   0.47733   9     11       33.692   3             0.18372         38.26667    5.20543     428.6176      1188     0.36364
  TNS1        240   0.62199   7     7        32.135   1             0.18372         35.18333    5.07588     8.55088       56       0.80952
  COL1A1      142   0.32239   11    11       33.115   4             0.1531          34.35       4.85212     350.8601      1722     0.34545
  FOXO1       134   0.31924   10    10       33.841   4             0.18372         37.95       5.24076     203.7761      800      0.35556
  FOXO3       131   0.4082    8     11       32.054   2             0.18372         36.85       5.09943     398.0874      1268     0.25455
  DICER1      121   0.64826   5     6        29.184   2             0.18372         34.18333    5.02877     157.1734      434      0.66667
  CXCR4       58    0.37904   8     8        32.284   11            0.18372         36.86667    5.2172      178.6964      600      0.46429
  MUC1        52    0.47549   6     8        30.378   5             0.18372         36.43333    5.1701      366.1695      864      0.39286
  IGFBP5      32    0.36588   7     7        28.18    1             0.1531          32.31667    4.82856     193.0638      622      0.47619
  LAMC1       28    0.38039   6     6        26.728   1             0.1531          30.46667    4.67546     88.60129      278      0.53333
  CALU        27    0.56839   4     7        27.046   7             0.1531          32.88333    4.87567     368.5913      1006     0.33333
  STC2        25    0.56839   4     5        21.431   2             0.13123         27.22619    4.34571     112.2128      258      0.6
  FSTL3       24    0.56839   4     4        21.367   1             0.13123         26.34286    4.28682     0             0        1
  SOCS3       21    0.38039   6     7        29.643   3             0.18372         34.51667    5.02877     250.4977      792      0.38095
  FBXW7       20    0.38039   6     6        29.119   1             0.18372         34.18333    5.02877     77.23846      304      0.53333
  FBN2        8     0.37893   4     4        23.641   2             0.1531          27.75       4.48703     26.03518      280      0.66667
  KLF5        7     0.46346   3     4        24.062   2             0.18372         32.68333    4.96989     59.30048      238      0.5
  PRKAA1      7     0.30898   3     6        25.204   1             0.1531          30.03333    4.6048      61.26671      174      0.13333
  PRRX1       6     0.46346   3     3        23.368   1             0.1531          27.36667    4.48703     0             0        1
  TGFBI       6     0.46346   3     3        23.103   1             0.1531          28.15       4.53414     0             0        1
  COL5A2      6     0.2842    4     4        19.627   1             0.13123         24.70952    3.9924      5             10       0.5
  PPP2R5E     5     0         1     5        19.69    3             0.1531          30.61667    4.69902     302.8195      790      0
  CASP2       5     0.30898   3     4        20.746   2             0.18372         31.93333    4.88745     143.4932      330      0.33333
  SERPINH1    5     0.30898   3     4        20.532   2             0.1531          28.4        4.52236     171.9268      490      0.33333
  TXNIP       4     0.30898   3     3        20.773   2             0.18372         32.1        4.93456     12.23252      76       0.66667
  PRDM1       4     0.30898   3     3        22.727   1             0.18372         31.1        4.85212     0.68182       4        0.66667
  B2M         4     0.30779   2     4        18.355   7             0.18372         32.53333    4.96989     716.2094      1514     0.33333
  CTNND1      4     0.30779   2     4        18.921   5             0.18372         32.68333    4.95811     480.2316      832      0.16667
  APAF1       4     0.30898   3     3        20.821   1             0.18372         31.76667    4.89922     4.66667       16       0.66667
  SIN3B       3     0.30779   2     3        18.56    2             0.18372         32.26667    4.95811     154           238      0.33333
  FNBP1       3     0         1     3        4.766    3             0.1531          22.36667    3.81574     277.7906      550      0
  LDLR        3     0         1     3        11.833   5             0.18372         27.81667    4.58125     537.7906      1026     0
  FRK         3     0.30779   2     3        7.811    2             0.18372         24.4        4.15727     154           298      0.33333
  MYO6        3     0         1     3        8.446    3             0.1531          24.88333    4.19261     218.1825      368      0
  SESN2       3     0.30779   2     3        21.783   1             0.18372         32.85       5.01699     34.11001      178      0.33333
  RAB27A      3     0.30779   2     3        8.435    4             0.18372         24.86667    4.20438     326.2094      692      0.33333
  RAB34       3     0         1     3        4.339    3             0.1531          20.68333    3.43888     210.7381      444      0
  CLOCK       3     0         1     3        16.66    1             0.1531          28.1        4.58125     65.63025      158      0
  PERP        2     0         1     2        12.381   2             0.18372         30.6        4.84034     43.91725      162      0
  CALM2       2     0         1     2        8.433    1             0.13123         22.04286    3.76863     29.95094      44       0
  RARG        2     0         1     2        14.151   2             0.18372         30.93333    4.87567     28.30952      88       0
  WASF2       2     0         1     2        3.067    1             0.13123         18.80952    3.06202     38.52872      68       0
  MBNL1       2     0         1     2        10.944   1             0.1531          24.3        4.15727     10.72727      40       0
  MYOCD       2     0         1     2        14.687   1             0.1531          25.3        4.23971     2.05556       8        0
  FAM46A      2     0         1     2        1.568    3             0.03488         2           0.12209     2             2        0
  PRKAR1A     2     0         1     2        16.389   1             0.1531          27.86667    4.53414     4.43252       46       0
  CITED2      2     0         1     2        12.229   1             0.1531          25.05       4.21616     3.06667       8        0
  PPP1R10     2     0         1     2        11.151   1             0.1531          24.55       4.18083     27.70586      98       0
  PPP1R9B     2     0         1     2        8.77     1             0.13123         22.55952    3.8393      7             8        0
  PTBP2       2     0         1     2        8.932    1             0.1531          23.3        4.01595     3.55385       8        0
  P4HA2       2     0.30779   2     2        13.847   1             0.13123         23.54286    3.95707     0             0        1
  GALNT6      2     0.30779   2     2        11.642   1             0.1531          24.96667    4.27504     0             0        1
  FBXL7       2     0.30779   2     2        15.652   1             0.1531          24.63333    4.19261     0             0        1
  MUC17       2     0.30779   2     2        11.691   1             0.1531          24.96667    4.27504     0             0        1
  RER1        1     0         1     1        8.885    1             0.13123         22.69286    3.96884     0             0        0
  AMOTL1      1     0         1     1        12.027   1             0.1531          26.06667    4.42815     0             0        0
  SPAG9       1     0         1     1        10.867   1             0.18372         29.93333    4.81679     0             0        0
  SIRPA       1     0         1     1        10.606   1             0.1531          25.31667    4.35748     0             0        0
  AHCYL2      1     0         1     1        1.322    1             0.02326         1           0.06977     0             0        0
  HIGD1A      1     0         1     1        1.322    1             0.02326         1           0.06977     0             0        0
  PHACTR2     1     0         1     1        1.374    1             0.01744         1.5         0.10465     0             0        0
  MSL2        1     0         1     1        2.175    1             0.13123         17.24286    2.90891     0             0        0
  AFF1        1     0         1     1        10.166   1             0.1531          25.1        4.2986      0             0        0
  TMF1        1     0         1     1        2.402    1             0.13123         16.14524    2.53205     0             0        0
  C4orf19     1     0         1     1        6.234    1             0.1531          22.86667    4.05128     0             0        0
  STRN4       1     0         1     1        6.291    1             0.13123         21.64286    3.79219     0             0        0
  BBX         1     0         1     1        6.08     1             0.1531          22.75       4.05128     0             0        0
  SPATA5      1     0         1     1        1.289    1             0.02326         1           0.06977     0             0        0
  UBE4B       1     0         1     1        1.289    1             0.02326         1           0.06977     0             0        0
  PRDM16      1     0         1     1        11.749   1             0.18372         29.93333    4.81679     0             0        0
  C10orf10    1     0         1     1        9.952    1             0.1531          24.38333    4.19261     0             0        0
  OPTN        1     0         1     1        3.585    1             0.13123         18.7619     3.28578     0             0        0
  TSPAN12     1     0         1     1        4.562    1             0.1531          20.43333    3.67442     0             0        0
  FNDC3B      1     0         1     1        1.358    1             0.01744         1.5         0.10465     0             0        0
  EDEM3       1     0         1     1        7.224    1             0.13123         20.55952    3.61553     0             0        0
  CCNT2       1     0         1     1        10.511   1             0.1531          25.1        4.2986      0             0        0
  NHLRC3      1     0         1     1        3.536    1             0.1531          18.5        3.25045     0             0        0
  NFYA        1     0         1     1        11.172   1             0.18372         29.93333    4.81679     0             0        0
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